Challenges in monoclonal antibody-based therapies (Q37398725)

20 August 2017

1 reference

title

Challenges in monoclonal antibody-based therapies (English)

1 reference

20 August 2017

1 reference

1 reference

5

1 reference

20 August 2017

3

Diana Schenkwein

1 reference

20 August 2017

4

Jani K Räty

1 reference

20 August 2017

Haritha Samaranayake

1

1 reference

PubMed ID

19234897

20 August 2017

Thomas Wirth

series ordinal

2

1 reference

PubMed ID

19234897

20 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

41

1 reference

20 August 2017

5

1 reference

20 August 2017

322-331

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

20 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Intrabodies as drug discovery tools and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Economic aspects of commercial manufacture of biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Therapeutic antibody gene transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Elimination mechanisms of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Monoclonal antibody-based genetic immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Challenges in therapeutic glycoprotein production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by Mammalian cell systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Glycosylation of therapeutic proteins in different production systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Current status of antibody therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Stable antibody expression at therapeutic levels using the 2A peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Basic concepts in Q membrane chromatography for large-scale antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Pharmacokinetic aspects of biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

LDL stimulates mitogen-activated protein kinase phosphatase-1 expression, independent of LDL receptors, in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Antibodies and gene therapy: teaching old 'magic bullets' new tricks

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Structure-immunogenicity relationships of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Immunotherapy: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Production of human antibody repertoires in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Stevens-Johnson syndrome after treatment with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Regulatable gene expression systems for gene therapy applications: progress and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Cell microencapsulation technology for biomedical purposes: novel insights and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Encapsulated cell technology: from research to market.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Characterization of adeno-associated virus genomes isolated from human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Genetic fate of recombinant adeno-associated virus vector genomes in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Monoclonal antibodies produced by muscle after plasmid injection and electroporation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07853890802698842

10.1080/07853890802698842

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19234897